Antagonist anti-CD40 monoclonal antibodies and methods for their use

US8637032B2 · kind B2 · utility

Assignee

• Novartis Vaccines and Diagnostics, Inc. · US

Inventors

• Li Long · Hercules, US
• Mohammad Luqman · Emeryville, US
• Asha Yabannavar · Lafayette, US
• Isabel Zaror · Orinda, US
• Sang Hoon Lee · Jeomgok-myeon, KR
• Deborah Hurst · Piedmont, US

Key dates

• Filing date: Sep 12, 2012
• Grant date: Jan 28, 2014
• Expiry date: Sep 12, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.